The start-up making drugs in space, then sending them to Australia at 30,870 km/h
For example, is it possible that space capsules are orbiting the Earth - while they make advanced drug compounds?
And then the same capsules are returning to terra firma after travelling at 25 times the speed of sound into our atmosphere?
Why, yes...
And when they return to Earth, they are returning to Australia?
Yes, again.
'It's actually much less futuristic than it sounds,' says Will Bruey, CEO of Varda Industries, the company launching the drug-factory capsules.
'On average three SpaceX Starlink satellites are launched per day, and our spacecraft is simpler, quite frankly, than a Starlink satellite,' he says.
And, while it's early days for California-based Varda, founded in 2021, the pace of launch for these capsules – whose journey takes them from the US, to low earth orbit, to a South Australian testing range for recovery – is expected to increase.
The start-up is attempting to create a viable business of manufacturing drugs in space, where the lack of gravity unlocks the possibility of new, more effective – and more profitable – drug compounds that can't be made on Earth.
Being in space, the limits on the scale of manufacturing are different to an Earth-bound enterprise – both in the molecular quality of what can be produced and, potentially one day, the scale of the production facility.
For now, the company's future depends on how effectively and profitably it can formulate drugs – or at least the most effective primary active pharmaceutical ingredient – in orbit.
When discussing drug production, Bruey compares microgravity (ultra-low gravity in orbit) to the effect that refrigeration has had on drug production since it was invented.
Before refrigeration existed, people would have asked, how could it create value for pharmaceuticals? Today, refrigeration is a fundamental part of drug and vaccine manufacturing, shipping and storage. It reduces the risk of contamination and helps ensure the drugs are effective. Profitable drug manufacturing would be almost unthinkable without it.
One day, space-based drugs may be discussed the same way. 'The way the pharmaceutical industry will think about [Varda] shortly is just another piece of equipment.'
Even the name of the spacecraft – the W in Varda's W-series capsule – unofficially stands for 'Winnebago' (or caravan in American English) used in TV series Breaking Bad, which is itself a story about the remote, compartmentalised cooking up of drugs.
'Instead of going to the desert, we're going to space,' Bruey said.
Likewise, Varda is hauling its equipment to a destination to make its batch, then coming back. 'So that's what we'll be doing. And we'll just be increasing the amount of Winnebagos that are going out to space and back.'
'There's a lot of low-hanging fruit and optimisation to be done in that paradigm.'
Any drug with a formulation improvement worth more than $US200 a gram is viable for Varda to manufacture today. But Varda forecasts it can drive down the cost from $US200 to $US20 'pretty easily by just making our systems more reusable'.
To push lower than that, the company will construct a permanent station with manufacturing equipment that can be used for multiple drugs, Bruey says.
Much of the science around drugmaking in space has been done. There have been numerous experiments on pharmaceuticals, for example, on the International Space Station.
Varda hopes to have a space-made drug in humans by the end of the decade. In an era of sagging productivity, it's worth considering the value of genre-melding new ventures.
The question is: how much demand is there for a service that is new to the world? And on Earth – in Australia – how many re-entries could we see?
Adelaide-based company, Southern Launch, was formed in 2017 as a spaceport operator providing launch services. It has since begun offering orbital re-entry services for customers like Varda.
Their range, at Koonibba in South Australia, enjoys clearer skies with less air traffic than test ranges in the US, giving more flexibility to Varda and other clients, Southern Launch says.
Southern Launch CEO Lloyd Damp said the missions conducted for Varda so far, 'mark an incredible step forward for Australia as the global landing site for re-entries and the in-space manufactured goods the capsules carry.'
Investing in an unproven business model is riskier than investing in say, inner city residential property. But Bruey sees Varda as carving out a niche that can expand as demand grows.
'Basically, there's only four fundamental forces of physics, and gravity is one of them, and we have a knob on [it], and no other company does.' (If you're wondering, the three other forces are: electromagnetism and the strong and weak nuclear forces).
Bruey knows about physics because he studied the subject at Cornell University before founding a couple of companies and working at Elon Musk's SpaceX.
Bruey then met up with Delian Asparouhov, who was looking to invest in a company that could do this work. Asparouhov was looking for someone with Bruey's background and who 'was willing to drop everything and go on this adventure'.
Varda now has backing from Khosla Ventures, Lux Capital, Caffeinated Capital, Founders Fund, and General Catalyst. It has raised $US187 million in a new funding round this month, bringing the total capital raised to $US329 million.
The bet that money can be made by low-orbit manufacturing has caught the attention of SpaceX, which reportedly has plans to get into the space-drug game by manufacturing too.
Elon Musk's company plans to use its massive – and recently unlucky – Starship rocket for the purpose, according to Bloomberg. Sources close to Varda call the report about SpaceX's plan, called Starfall, a 'validation' of Varda's business model.
Like SpaceX, Varda's goal isn't science, it's business: advanced, space-tech business, with the potential to unlock a huge new market that could one day involve large in-orbit factories. The in-space manufacturing market could be worth $US10 billion in five years, according to McKinsey.
But exploiting a fundamental force of physics for profit comes with some hard realities. If you send the capsule into space, you must find a reliable place to recover the spacecraft – closing the loop on the production process.
That's where Australia comes in.
Varda's first craft W-1, launched in June 2023, was due to return in July, but instead got delayed as the company sought permission for the landing in Utah. It remained in orbit for eight months while the details of a new license were resolved between government authorities.
While W-1 was in orbit, Varda reached out to Australia's space industry, looking for reliable space return services.
W-1's February 2024 return coincided with Varda being granted a 'Part 450 re-entry license' from the FAA's Office of Space Transportation, part of a new process to accommodate repeated missions common in commercial space.
Varda now has a FAA license which allows the company to launch and re-enter a craft without spelling out the identical parameters of the mission on repeated applications.
When Varda's W-2 landed in South Australia, Enrico Palermo, head of the Australian Space Agency said it highlighted 'the opportunity for Australia to become a responsible launch and return hub for the global space community, capitalising off the geographic advantages of our expansive continent.'
Unlike crewed missions, which must gently skim into the atmosphere without burning up to bring humans safely home, Varda's missions comes in 'ballistically, as if it's like a missile'.
In that phase, the Winnebagos achieve Mach 25, twenty-five times the speed of sound, or 30,870 kilometres per hour.
Varda has attached a camera to the capsule to capture the dramatic re-entry footage, which looks something like a gas log on overdrive. In space.
The pink glow you see is plasma, Bruey says, from the capsule moving so fast and creating so much heat 'it's literally ripping the molecules in the atmosphere apart and ripping away their electrons'.
'The streaks of what looks like fire is the heat shield 'ablating', that is the little pieces coming off intentionally to take away the heat, shedding it from the spacecraft.'
So far, Varda has created a crystal form of an HIV drug ritonavir in space.
It has research collaborations with large pharma brands, whose names Varda would not give, citing non-disclosure agreements.
W-2 and W-3 landed in February and May 2025 at Koonibba Test Range in South Australia. W-4 is currently in orbit. Varda says it is on track for four missions in 2025 – with plans to expand to a double-capsule mission in 2026. From there, the pace is expected to increase to a weekly pace.
Veteran space industry observer and contributor Brett Biddington says Australia is 'well-suited to support the recovery of payloads from space' with a historical record that is 'unblemished'.
'Whether a viable business can be made just from recovery support is another question,' he says.
He expects that the 'activity will be lumpy and sporadic' and can best thought of as a 'supplementary income stream' to one that is more reliable.
Varda's plan isn't to create a new business alone, but the industry needed to support and grow the enterprise.
With the capsules going up and coming back, we will soon know if Varda is successful.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Sydney Morning Herald
2 hours ago
- Sydney Morning Herald
Australian energy giant ditches US plant as Trump attacks green power
Woodside, the largest Australian oil and gas company, has abandoned plans to build a lower-carbon fuels plant in the United States as energy users and producers reel from Donald Trump's decision to slash tax breaks for green technologies. The Perth-based energy giant told investors on Wednesday it would take a $US140 million ($214 million) profit hit after deciding to walk away from the H2OK liquid hydrogen project it had been planning in Oklahoma, blaming the rising cost of making cleaner hydrogen and weaker-than-expected customer demand. 'We have made the decision to exit the H2OK project, demonstrating our disciplined approach to portfolio management,' Woodside chief executive Meg O'Neill said on Wednesday. Woodside, a producer of oil and liquefied natural gas (LNG), is pursuing the development of lower-carbon hydrogen as part of its climate transition strategy. Because hydrogen emits only water vapour when burned, it is considered by many to be a promising climate-friendly energy source that could eventually substitute fossil fuels and help clean up heavy-polluting industries, as long as it is made using low- or zero-carbon energy sources. Woodside's H2OK would have used an electrolyser, powered by the electricity grid, to split water into hydrogen and oxygen. However, Woodside announced it was pausing the H2OK project in January, shortly after Donald Trump's return to the White House. It also scrapped a separate plan to build a concentrated solar thermal energy facility in California through a partnership with Heliogen, a company backed by billionaire Bill Gates. While not directly attributing those decisions to Trump's energy agenda, Woodside at the time said it needed to consider the implications of the administration's pledge to dismantle support for US clean energy investments, including halting the disbursement of funds from the $567 billion Inflation Reduction Act, which had been offering generous tax breaks for renewable developers. This month, Trump secured the passage of a giant tax and domestic policy bill through Congress, which will make it cheaper and easier for companies to drill and produce fossil fuels, while cutting funding for electric cars and wind and solar farms. Woodside remains committed to one clean energy investment in the US, the Beaumont lower-carbon ammonia project in Texas. The project was 95 per cent completed as of June 30, the company said.

The Age
2 hours ago
- The Age
Australian energy giant ditches US plant as Trump attacks green power
Woodside, the largest Australian oil and gas company, has abandoned plans to build a lower-carbon fuels plant in the United States as energy users and producers reel from Donald Trump's decision to slash tax breaks for green technologies. The Perth-based energy giant told investors on Wednesday it would take a $US140 million ($214 million) profit hit after deciding to walk away from the H2OK liquid hydrogen project it had been planning in Oklahoma, blaming the rising cost of making cleaner hydrogen and weaker-than-expected customer demand. 'We have made the decision to exit the H2OK project, demonstrating our disciplined approach to portfolio management,' Woodside chief executive Meg O'Neill said on Wednesday. Woodside, a producer of oil and liquefied natural gas (LNG), is pursuing the development of lower-carbon hydrogen as part of its climate transition strategy. Because hydrogen emits only water vapour when burned, it is considered by many to be a promising climate-friendly energy source that could eventually substitute fossil fuels and help clean up heavy-polluting industries, as long as it is made using low- or zero-carbon energy sources. Woodside's H2OK would have used an electrolyser, powered by the electricity grid, to split water into hydrogen and oxygen. However, Woodside announced it was pausing the H2OK project in January, shortly after Donald Trump's return to the White House. It also scrapped a separate plan to build a concentrated solar thermal energy facility in California through a partnership with Heliogen, a company backed by billionaire Bill Gates. While not directly attributing those decisions to Trump's energy agenda, Woodside at the time said it needed to consider the implications of the administration's pledge to dismantle support for US clean energy investments, including halting the disbursement of funds from the $567 billion Inflation Reduction Act, which had been offering generous tax breaks for renewable developers. This month, Trump secured the passage of a giant tax and domestic policy bill through Congress, which will make it cheaper and easier for companies to drill and produce fossil fuels, while cutting funding for electric cars and wind and solar farms. Woodside remains committed to one clean energy investment in the US, the Beaumont lower-carbon ammonia project in Texas. The project was 95 per cent completed as of June 30, the company said.

Sydney Morning Herald
3 hours ago
- Sydney Morning Herald
Marmota expands drilling program at high-grade SA gold target
Marmota Limited has extended its maiden drilling program at its proven gold-mineralised Greenewood prospect in the northwestern part of the company's extensive multi-commodity Gawler Craton tenements in South Australia. It now plans to drill about 12,500 metres at an average downhole depth of 90m to deliver a maiden campaign far surpassing all the previous drilling metres put into the Greenewood prospect. The company has so far completed 61 holes in July for 5108m, with the drilling crew averaging about 284m per day. Marmota expects to continue the program for a further four to five weeks. The company flagged its drilling proposal and launched its new program in early July, following a detailed review of Greenewood's historic data. 'Marmota's Gawler gold project is progressing beautifully. We are delighted to carry out our maiden program at the nearby Greenewood gold deposit.' Marmota Limited chairman Dr Colin Rose The review found that gold mineralisation was discovered at the prospect during ASX-listed Tyranna Resources' 2016 reverse circulation drilling campaign to follow up anomalous gold results from a 2003 rotary air-blast (RAB) drilling program. Tyranna drilled the prospect further in 2017 and 2018, before moving away from gold to pursue lithium in Angola. Marmota acquired Tyranna's South Australian gold assets in 2020-2021. Tantalisingly, Marmota's reappraisal of the old gold assays during its recent data review unveiled some serious hits in Tyranna's reverse circulation drill tests. These include a best run in one hole of 1 metre assaying 53 grams per tonne (g/t) gold within a wider interval of 14m at 6g/t gold. A second hole hit 1m going 37g/t gold within a wider interval of 22m at 4g/t gold, while a third hole nailed 1m running 21g/t gold in a broader interval of 13m at 3.4g/t gold. A fourth hole bored through a further 1m interval assaying 29g/t within a 5m intercept going 10g/t gold.